AxoGen, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021
Management now expects 2021 revenue to be approximately $127.3 million and continues to expect full-year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.48 USD | +3.27% |
|
+23.12% | +38.80% |
01/07 | Raymond James Initiates AxoGen at Outperform With $13 Price Target | MT |
24/06 | Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix | CI |
1st Jan change | Capi. | |
---|---|---|
+38.80% | 40Cr | |
+4.57% | 21TCr | |
+8.61% | 19TCr | |
+26.34% | 16TCr | |
+33.90% | 11TCr | |
+2.17% | 6.55TCr | |
+14.50% | 5.29TCr | |
-3.30% | 4.53TCr | |
-3.98% | 3.97TCr | |
+6.66% | 3.77TCr |